phentermine and Polycystic Ovary Syndrome

phentermine has been researched along with Polycystic Ovary Syndrome in 1 studies

Phentermine: A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.

Polycystic Ovary Syndrome: A complex disorder characterized by infertility, HIRSUTISM; OBESITY; and various menstrual disturbances such as OLIGOMENORRHEA; AMENORRHEA; ANOVULATION. Polycystic ovary syndrome is usually associated with bilateral enlarged ovaries studded with atretic follicles, not with cysts. The term, polycystic ovary, is misleading.

Research

Studies (1)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Absolute Body Weight

Treatment effect on body weight at 24 weeks of treatment (NCT02635386)
Timeframe: 24 weeks of treatment

Android-Gynoid Ratio (AGR) as Determined by DEXA

treatment impact on measure of central adiposity as determined by android/gynoid ratio (NCT02635386)
Timeframe: 24 weeks of treatment

Body Mass Index (BMI)

Treatment efficacy in reducing body mass at 24 weeks of treatment (NCT02635386)
Timeframe: 24 weeks of treatment

Central Adiposity (Waist Circumference)

Treatment effect on loss of central adiposity after 24 weeks (NCT02635386)
Timeframe: 24 weeks of treatment

Change in Percent Body Weight

Treatment effect on change in percent body weight from baseline (NCT02635386)
Timeframe: Change from baseline (time 0) to study end (24 weeks)

Corrected First Phase Insulin Secretion (IGI/HOMA-IR)

Treatment effect on insulin secretion from 0 to 30 minutes after glucose load corrected for by fasting insulin sensitivity. A higher score shows improved first phase insulin secretion in response to glucose (NCT02635386)
Timeframe: 24 weeks of treatment

Dehydroepiandrosterone Sulfate (DHEA-S) Levels

Treatment effect on blood concentrations of DHEA-S (NCT02635386)
Timeframe: 24 weeks of treatment

Diastolic Blood Pressure (DBP)

Treatment effect on DBP after 24 weeks (NCT02635386)
Timeframe: 24 weeks of treatment

Fasting Blood Glucose

Treatment impact on fasting concentration of glucose in the blood (NCT02635386)
Timeframe: 24 weeks of treatment

Fasting Insulin Sensitivity (HOMA-IR)

Treatment effect on the ratio HOMA-IR which is insulin resistance measure derived from fasting blood glucose and insulin and is calculated by insulin (mU/ml)*glucose (mmol/L)/22,5. The higher thenumber the more insulin resistant. (NCT02635386)
Timeframe: 24 weeks of treatment

Free Androgen Index (FAI)

Treatment effect on FAI calculated from total testosterone divided by sex hormone binding globulin (SHBG) levels. A higher score indicates a worse outcome. (NCT02635386)
Timeframe: 24 weeks of treatment

Matsuda Sensitivity Index Derived From the OGTT(SI OGTT)

The SI IOGTT is a measure of peripheral insulin sensitivity derived from the values of Insulin (microunits per milliliter) and Glucose (milligrams per deciliter) obtained from the OGTT and the corresponding fasting values. SI (OGTT) = 10,000/ [(G fasting x I fasting) x (G OGTTmean x I OGTTmean)], where fasting glucose and insulin data are taken from time 0 of the OGTT and mean data represent the average glucose and insulin values obtained during the entire OGTT. The square root is used to correct for nonlinear distribution of insulin, and 10,000 is a scaling factor in the equation. The higher value, the more sensitive to insulin. (NCT02635386)
Timeframe: 24 weeks of treatment

OGTT Mean Blood Glucose (MBG)

Treatment effect on MBG measured during the oral glucose tolerance test (NCT02635386)
Timeframe: 24 weeks of treatment

Oral Disposition (Insulin Sensitivity-insulin Secretion) Index

An estimation of β-cell compensatory function, the insulin secretion-sensitivity index (IS-SI) will be derived by applying the concept of the oral disposition index to measurements obtained during the 2-h OGTT and calculated as the index of insulin secretion factored by insulin sensitivity (ΔINS/ΔPG 30 x Matsuda SIOGTT) from the OGTT. A higher score shows improved pancreatic insulin responsiveness relative to resistance. (NCT02635386)
Timeframe: 24 weeks of treatment

Systolic Blood Pressure (SBP)

Treatment effect on SBP after 24 weeks of treatment (NCT02635386)
Timeframe: 24 weeks treatment

Total Body Fat (%) by DEXA

Treatment impact on percent total body fat by DEXA (NCT02635386)
Timeframe: 24 weeks of treatment

Total Cholesterol Levels

Treatment effect on blood concentrations of total cholesterol (NCT02635386)
Timeframe: 24 weeks of treatment

Total Fat Mass (kg) Evaluated by DEXA

Treatment impact on total fat mass by DEXA (NCT02635386)
Timeframe: 24 weeks of treatment

Total Testosterone Concentrations

Treatment effect on blood concentrations of total testosterone (NCT02635386)
Timeframe: 24 weeks of treatment

Triglyceride (TRG) Levels

Treatment effect on blood concentrations of triglycerides (NCT02635386)
Timeframe: 24 weeks of treatment

Trunk/Leg Fat Ratio by DEXA

Treatment impact on trunk/limb ratio (measure of central adiposity) by DEXA (NCT02635386)
Timeframe: 24 weeks of treatment

Waist-to-Height Ratio (WHtR)

Treatment impact on WHtR which is a measure of central adiposity (NCT02635386)
Timeframe: 24 weeks of treatment

Waist-to-Hip Ratio (WHR)

Treatment impact on central adiposity after 24 weeks (NCT02635386)
Timeframe: 24 weeks of treatment

Trials

1 trial available for phentermine and Polycystic Ovary Syndrome